{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:32:52Z","timestamp":1790371972865,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.urolonc.2024.12.265","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T03:34:28Z","timestamp":1736048068000},"page":"269.e1-269.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic significance of body mass index in patients with metastatic renal cell carcinoma receiving first-line therapies"],"prefix":"10.1016","volume":"43","author":[{"given":"Keigo","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-6074","authenticated-orcid":false,"given":"Kosuke","family":"Takemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Urasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yoneoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiko","family":"Oguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Numao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Yonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.12.265_bib0001","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.eururo.2018.08.036","article-title":"Epidemiology of renal cell carcinoma","volume":"75","author":"Capitanio","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0002","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14740\/wjon1279","article-title":"Epidemiology of renal cell carcinoma","volume":"11","author":"Padala","year":"2020","journal-title":"World J Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0004","doi-asserted-by":"crossref","first-page":"3574","DOI":"10.1200\/JCO.2018.79.1905","article-title":"Epidemiology and risk factors for kidney cancer","volume":"36","author":"Scelo","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0005","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/ijo.2016.171","article-title":"Renal cell carcinoma survival and body mass index: a dose-response meta-analysis reveals another potential paradox within a paradox","volume":"40","author":"Bagheri","year":"2016","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0006","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/JU.0000000000001377","article-title":"A systematic review and meta-analysis of the significance of body mass index on kidney cancer outcomes","volume":"205","author":"Kim","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0007","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0008","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.1007\/s00432-022-04173-0","article-title":"Real world data on IO-based therapy for metastatic renal cell carcinoma","volume":"149","author":"Stuhler","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0009","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1470-2045(19)30797-1","article-title":"Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study","volume":"21","author":"Sanchez","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0010","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s00330-022-09345-7","article-title":"Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study","volume":"33","author":"Wang","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0011","doi-asserted-by":"crossref","first-page":"e000725","DOI":"10.1136\/jitc-2020-000725","article-title":"Obesity diminishes response to PD-1-based immunotherapies in renal cancer","volume":"8","author":"Boi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2023.05.006","article-title":"Relationship between pretreatment body composition and clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line Ipilimumab plus Nivolumab","volume":"21","author":"McManus","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0013","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0140-6736(02)09512-0","article-title":"WHO reassesses appropriate body-mass index for Asian populations","volume":"360","author":"Choo","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0014","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41387-018-0068-3","article-title":"Allometric scaling of weight to height and resulting body mass index thresholds in two Asian populations","volume":"9","author":"Hood","year":"2019","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1470-2045(18)30078-0","article-title":"Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis","volume":"19","author":"McQuade","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0016","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s44324-024-00007-4","article-title":"Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox","volume":"2","author":"Vick","year":"2024","journal-title":"NPJ Metab Health Dis"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.682449","article-title":"Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology: a real-world study on behalf of Meet-URO group (MeetUro-7b)","volume":"11","author":"Stellato","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0018","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eururo.2023.01.001","article-title":"Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma","volume":"84","author":"Ernst","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0019","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40425-019-0512-5","article-title":"Complex inter-relationship of body mass index, gender and serum creatinine on survival: exploring the obesity paradox in melanoma patients treated with checkpoint inhibition","volume":"7","author":"Naik","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0020","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jamaoncol.2019.5241","article-title":"Association between body mass index and overall survival with Immune checkpoint inhibitor therapy for advanced non-small cell lung cancer","volume":"6","author":"Kichenadasse","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0021","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/jamaoncol.2021.0019","article-title":"Assessment of immune checkpoint inhibitors and genomic alterations by body mass index in advanced renal cell carcinoma","volume":"7","author":"Lalani","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.coph.2015.04.003","article-title":"Cachexia and sarcopenia: mechanisms and potential targets for intervention","volume":"22","author":"Argiles","year":"2015","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0023","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s10147-017-1122-1","article-title":"Biomarkers to predict prognosis and response to checkpoint inhibitors","volume":"22","author":"Yuasa","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0024","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41591-018-0221-5","article-title":"Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade","volume":"25","author":"Wang","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2024.12.265_bib0025","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.euros.2022.03.002","article-title":"Impact of body mass index on survival outcomes of patients with metastatic renal cell carcinoma in the immuno-oncology era: a systematic review and meta-analysis","volume":"39","author":"Takemura","year":"2022","journal-title":"Eur Urol Open Sci"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924010457?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924010457?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T03:43:20Z","timestamp":1741664600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924010457"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1078143924010457"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.265","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prognostic significance of body mass index in patients with metastatic renal cell carcinoma receiving first-line therapies","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.12.265","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}